Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Marco Antônio Schilling"'
Autor:
Márcia Leite, Alice Zelmanowicz, Tânia Hellwig, Denise Almeida, Mauro Gross, Gilca Natchigal, Waldir Veiga Pereira, Jorge Neumann, Lucia Mariano da Rocha Silla, Marcelo Capra, Virginia Maria Coser, Líbia Vilella, Marco Antônio Schilling, Mario Sérgio Fernandes, Giorgio Adriano Paskulin
Publikováno v:
Leukemia & Lymphoma. 48:2381-2386
Rio Grande do Sul (RS), in South Brazil, with about 10 million inhabitants, is known for its agricultural activities and consequent increased human exposure to toxic agents. Patients with de novo acute myeloid leukemia (AML) were included based on in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d1b3b9e054e58b4ec1e3445d160734c
https://doi.org/10.1080/10428190701713622
https://doi.org/10.1080/10428190701713622
Autor:
Tânia Hellwig, Mariza Shaan, Tito Vanelli Costa, Juarez Fontoura Silveira, Raquel Breunig, Adriana Zardo, Mayde Seadi Torriani, Denise Almeida, Lucia Mariano da Rocha Silla, Luis Carlos Zanandrea Contin, Mario Sérgio Fernandes, Moema Nene, Tahiane de Brum Soares, Tiago Daltoe, Marco Antônio Schilling, Mariangela Moschen, Joao Ricardo Friedrisch, Marcelo Capra, Laura Fogliatto, Liane Esteves Daudt, Katia Fassina
Publikováno v:
Blood. 124:5536-5536
Background Monitoring response to TKI therapy is one of the key management strategies of chronic myeloid leukemia (CML). Early molecular response to first-line TKI therapy is emerging as an effective prognostic factor indicator of long-term durable r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f2eef8321ee0d6ded820e58c77e4216
https://doi.org/10.1182/blood.v124.21.5536.5536
https://doi.org/10.1182/blood.v124.21.5536.5536
Autor:
Mariangela Moschen, Tito Vanelli Costa, Tânia Hellwig, Juarez Fontoura Silveira, Marcelo Capra, Mariza Shaan, Adriana Zardo, Denise Almeida, Joao Ricardo Friedrisch, Raquel Breunig, Luis Carlos Zanandrea Contin, Liane Esteves Daudt, Mario Sérgio Fernandes, Tiago Daltoe, Lucia Mariano da Rocha Silla, Marco Antônio Schilling, Katia Fassina, Laura Fogliatto, Mayde Seadi Torriani, Moema Nene
Publikováno v:
Blood. 124:5542-5542
Sustained deep molecular response (MR4.5) after imatinib treatment defines a subgroup of patients with chronic myeloid leukemia (CML) with better outcome and that probably would be able to stop treatment in the future, according to results of clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c455cbd9b3a081e22e64c35ff70614a
https://doi.org/10.1182/blood.v124.21.5542.5542
https://doi.org/10.1182/blood.v124.21.5542.5542
Autor:
Laura Fogliatto, Marcelo Capra, Mariza Shaan, Tito Vanelli Costa, Raquel Breunig, Christina G S Fraga, Mayde Seadi Torriani, Lucia Silla, Liane Esteves Daudt, Mario Sérgio Fernandes, Denise Almeida, Marco Antônio Schilling, Tânia Hellwig, Katia Fassina, Sabrina Wisintainer, Mariangela Moschen, Tiago Daltoe, Adriana Zardo, Juliana Kratochvil, Viviane Magagnin Fernandes, Cheila Eickhoff, Moema Nene, Saozan Ahmad, Andréia Dias Almeida, Vitor Lenz
Publikováno v:
Blood. 122:5176-5176
Background Treatment of chronic myeloid leukemia with imatinib leads to disease remission in a majority of patients (pts), but in a subgroup of pts controlling the disease remains a challenge. One of the proposed prognostic factors for identifying th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a0bcb08be63425617a1ab25380bece8
https://doi.org/10.1182/blood.v122.21.5176.5176
https://doi.org/10.1182/blood.v122.21.5176.5176
Autor:
Saozan Ahmad, Sabrina Wisintainer, Viviane Magagnin Fernandes, Mariangela Moschen, Moema Nene, Mariza Shaan, Mario Sérgio Fernandes, Tito Vanelli Costa, Tiago Daltoe, Laura Fogliatto, Marco Antônio Schilling, Juliana Kratochvil, Cheila Eickhoff, Andréia Dias Almeida, Tânia Hellwig, Marcelo Capra, Adriana Zardo, Virginia Maria Coser, Márcia Leite, Lucia Mariano da Rocha Silla, Dayane Bohn Koshiyama, Denise Almeida, Waldir Veiga Pereira, Katia Fassina, Liane Esteves Daudt, Nathália Guterres Xavier, Dalnei Veiga Pereira, Vitor Lenz, Mayde Seadi Torriani
Publikováno v:
Blood. 118:4423-4423
Abstract 4423 Background Treatment of chronic myeloid leukemia with imatinib leads to disease remission in a majority of patient, but in some patients (pts) controlling the disease remains a challenge. One of the proposed prognostic factors for ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c7e7b2ed6e88ea21230d2eb7938cc2f
https://doi.org/10.1182/blood.v118.21.4423.4423
https://doi.org/10.1182/blood.v118.21.4423.4423
Autor:
Mayde Seadi Torriani, Liane Esteves Daudt, Mariza Shaan, Tânia Hellwig, Virginia Maria Coser, Dalnei Veiga Pereira, Andréia Dias Almeida, Saozan Ahmad, Waldir Veiga Pereira, Adriana Zardo, Denise Almeida, Marco Antônio Schilling, Laura Fogliatto, Mariangela Moschen, Viviane Magagnin Fernandes, Mario Sérgio Fernandes, Lucia Mariano da Rocha Silla, Marcelo Capra, Tito Vanelli Costa, Márcia Leite, Tiago Daltoe, Cheila Eickhoff, Moema Nene, Sabrina Wisintainer, Katia Fassina, Vitor Lenz, Juliana Kratochvil, Dayane Bohn Koshiyama, Nathália Guterres Xavier
Publikováno v:
Blood. 118:4425-4425
Abstract 4425 Adherence to imatinib therapy has proven to be a major determinant of treatment results, but the degree of impact and the determinants of nonadherence are still contradictory. There is no information regarding adherence to imatinib ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a89bc53fa3da07c644d95a253ed916f
https://doi.org/10.1182/blood.v118.21.4425.4425
https://doi.org/10.1182/blood.v118.21.4425.4425
Autor:
Gilca Nachtigal, Marco Antônio Schilling, Andréia Dias Almeida, Tito Vanelli Costa, Moema Nene, Erica Lammerhirt Ottoni, Marcelo Capra, Tânia Hellwig, Liane Esteves Daudt, Mayde Seadi Torriani, Laura Fogliatto, Mario Sérgio Fernandes, Mariza Shaan, Christina G S Fraga, Katia Fassina, Lucia Mariano da Rocha Silla, Adriana Zardo, Denise Almeida
Publikováno v:
Blood. 116:4487-4487
Abstract 4487 Background: Imatinib treatment for Chronic Myeloid Leukemia (CML) was first introduced in Brazil in 2001, initially used as second line therapy for patients resistant or intolerant to interferon (IFN). In 2008 imatinib was adopted as fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6764e77c733969bd19924c0b7fef044b
https://doi.org/10.1182/blood.v116.21.4487.4487
https://doi.org/10.1182/blood.v116.21.4487.4487
Autor:
Andréia Dias Almeida, Tito Vanelli Costa, Gilca Nachtigal, Katia Fassina, Adriana Zardo, Denise Almeida, Lucia Mariano da Rocha Silla, Liane Esteves Daudt, Mario Sérgio Fernandes, Christina G S Fraga, Marcelo Capra, Laura Fogliatto, Mariza Schaan, Moema Nene, Marco Antônio Schilling, Tânia Hellwig, Erica Lammerhirt Ottoni
Publikováno v:
Blood. 116:2300-2300
Abstract 2300 Introduction: Imatinib mesylate (Gleevec) treatment for Chronic Myelogenous Leukemia (CML) was first introduced in Brazil in 2003, initially used as second line therapy for patients resistant or intolerant to interferon. In 2004 imatini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6efab3bfc06b12c749d1e5ffa39e462b
https://doi.org/10.1182/blood.v116.21.2300.2300
https://doi.org/10.1182/blood.v116.21.2300.2300
Autor:
Marco Antônio Schilling, Adriana Wink, Ingrid Mito, Victor Hugo Lenz, Luciana Tagliari, Denise Pereira, Lisandra Dellacosta, Mariza Schaan, Adriana Zardo, Gilca Nachtigal, Waldir Veiga Pereira, Mario Sérgio Fernandes, Cheila Eickhof, Moema Nene, Tânia Hellwig, Virginia Maria Coser, Laura Fogliatto, Lucia Mariano da Rocha Silla, Dalnei Veiga Pereira, Aletea Zago, Marcelo Capra, Sabrina Wisenstein, Inez Guterrez, Roque Lorandi, Tito Vanelli
Publikováno v:
Blood. 112:4286-4286
CML is a well characterized disease with a known chromosomal abnormality. The inhibition of BCR-ABL protein tyrose kinase activity represented an advance in the treatment of this disease. Imatinib is effective in chronic, accelerated and blastic phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22a96fcf1af0992d997923d67cdcf708
https://doi.org/10.1182/blood.v112.11.4286.4286
https://doi.org/10.1182/blood.v112.11.4286.4286
Autor:
Marisa Schaan, Adriana Zardo, Denise Almeida, Laura Fogliatto, Ines Guterres, Adriana Winck, Marco Antônio Schilling, Mario Sérgio Fernandes, Aletea Zago, Sabrina Wisinteiner, Marcelo Capra, Tânia Hellwig, Lucia Mariano da Rocha Silla, Roque Lorandi
Publikováno v:
Blood. 108:4822-4822
Background: Imatinib mesylate (Glivec,Novartis), an inhibitor of Bcr-abl tyrosine kinase, is currently being used in the treatment of CML with hematological, cytogenetic and molecular response. In Brazil, this drug is approved by Health Department fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcd2f545a7e6918ece941826a9de4b14
https://doi.org/10.1182/blood.v108.11.4822.4822
https://doi.org/10.1182/blood.v108.11.4822.4822